First Revenues from Sales in Germany

Rua Bioscience is excited to announce the first revenues from sales of products in Germany after the first full month of sales. The response to the Rua products has exceeded our expectations and they been very well received by pharmacists and patients in the German market. In the first month of sale Rua has sold 13,000 grams or 28 pounds of dried flower product. The first revenues in Germany are a significant milestone for the company. As an early-stage medicinal cannabis company, achieving revenue is important to ensure the long-term sustainability of the company and returning value to our shareholders. The planning for this market launch by the combined marketing efforts of Nimbus Health and Rua Bioscience teams has been in the pipeline for many months and we are pleased to see the results of our efforts. With an established path to market and revenue, Rua and Nimbus Health plan to expand the product offering in the German market. In time, Rua will distribute the genetics from our Ruatorea facility through this same channel. Paul Naske, CEO of Rua Bioscience expressed his thanks to all the staff and stakeholders of Rua Bioscience who have worked hard over the recent months and years to establish this pathway to market. The team have been focused and methodical in their approach and dedication to the German market over many years. This is a significant milestone of the strategy that Rua put in place in 2019 to create sustainable revenue and a positive return to shareholders. For more information about Rua Bioscience please visit www.ruabioscience.com. ENDS The person who authorised this announcement: Paul Naske, Chief Executive Officer For shareholder enquiries please visit www.ruabio.com or contact: info@ruabio.com 0800 RUABIO End CA:00412645 For:RUA Type:GENERAL Time:2023-06-07 09:25:09